BTIM’s five (5) new human stem cell lines are now offered for research use only. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells. Read more…
Although congenital heart disease represents the most common major birth defect, scientists have not previously identified the common variation in the genes that give rise to it. Now genetics and cardiology researchers have discovered a genetic variant on chromosome 5 that strongly raises the risk of congenital heart disease. Read more…
A gene therapy technique restored some muscle function for months in patients with a certain type of muscular dystrophy. This is the first time such a feat has been performed in humans, with findings published at the annual meeting of the American Society of Gene & Cell Therapy. If replicated, the findings could provide hope for people with this and other forms of muscular dystrophy. Read more…
British scientists have launched the world’s first stem cell project to recreate a devastating and incurable brain disease in the laboratory.
SSS.V reports no statistical differences between the groups and but, the top-line primary endpoint results for the modified REGENESIS P2b stroke trial of NTx (R)-265 in acute stroke Read more…
Australia’s MSB received clearance from the US’s FDA to begin Phase 2 clinical trials of its “off-the-shelf” or allogeneic stem cell product NeoFuse™ for fusion of the cervical spine in the neck. Read more…
We are all looking for any signal that will propel a stock and one major indicator is the CEO investing his own money. Timothy Mayleben, CEO of ASTM filed another Form 4, this week with the SEC wiich is his 2nd open market purchase since becoming CEO in 12/09. Read more…
The FDA and the NIH launched a new website that, when fully developed, will provide a mechanism for the reporting of pre and post market safety data to the federal government. The new site, called the Safety Reporting Portal (SRP) will provide access to online reporting to analyze human and animal safety related events needed to protect the public. Read more…
CUR updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig’s disease) at Emory University in Atlanta, Georgia. Read more…
The Vatican praised scientists, who had created the world’s first synthetic cell, calling it an “interesting result” that could help cure disease. Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.